GlycoNex To Participate In BIO Asia-Taiwan 2025

Highlighting advancements in glycan-directed cancer immunotherapies and biosimilars

New Taipei City, Taiwan /PRNewswire/ - GlycoNex, Inc. (4168, hereinafter referred to as GNX), a clinical stage biotechnology company focused on the development of glycan-directed cancer immunotherapies, today announced its participation in the 2025 BIO Asia-Taiwan International Conference & Exhibition. The event will take place from July 23-27, 2025, at the Nangang Exhibition Center, Taipei.

At BIO Asia-Taiwan 2025, GlycoNex's leadership team will meet with investors, potential partners, and other industry stakeholders to discuss the company's strategic initiatives, clinical progress, and innovations in glycan-targeted therapies and biosimilar development. GlycoNex will highlight progress with its development programs, including GNX1021, its novel antibody drug conjugate (ADC), SPD8, a denosumab biosimilar currently in Phase 3 clinical trials, and GlycoSH, an anti-glycan antibody bank suitable for early drug discovery.

Details of the events are as follows:

About GlycoNex Inc.
GlycoNex Inc. is a clinical-stage biotechnology company focused on the development of glycan-directed cancer immunotherapies that effectively inhibit tumor growth while minimizing side effects. GlycoNex possesses a robust pipeline led by GNX102, a humanized monoclonal antibody (mAb) designed to target abnormal sugar molecules in cancer cells. GNX102 has successfully completed Phase 1 clinical trials with data demonstrating excellent safety and promising efficacy. GlycoNex is also advancing a portfolio of antibody-drug conjugates (ADCs) that precisely attack cancer cells while sparing healthy tissue, including GNX1021, its novel ADC that targets branched Lewis B/Y (bLeB/Y). GlycoNex is headquartered in New Taipei City, Taiwan. For more information, visit http://www.glyconex.com.tw.